Q2 2025 Merck KGaA Earnings Call Transcript
Key Points
- Merck KGaA (MKGAF) achieved a 2% organic sales growth and a 5% increase in EBITDA pre, indicating profitable growth despite challenging economic conditions.
- The Life Science sector showed strong performance with an 11% growth in Process Solutions, driven by robust order intake and a book-to-bill ratio comfortably above one.
- Healthcare sales grew organically by 4%, supported by double-digit growth in Mavenclad and Erbitux, and solid growth in the CM&E portfolio.
- The company successfully closed the acquisition of SpringWorks and the divestiture of Surface Solutions, enhancing its focus on high-tech applications and healthcare growth.
- Merck KGaA (MKGAF) maintained its EBITDA pre guidance midpoint despite currency headwinds and negative portfolio effects, demonstrating strong financial management.
- Electronics sales declined by 6% organically, primarily due to a significant drop in the DS&S business within Semiconductor Solutions.
- The company faced a stronger currency headwind on EBITDA pre than on sales, impacting financial results negatively.
- The financial result declined significantly due to a more negative interest result, reflecting tax items and lower interest income.
- Operating cash flow decreased due to higher tax and bonus payments, impacting liquidity.
- The Electronics sector experienced a margin decline due to nonrecurring items and foreign exchange headwinds, affecting profitability.
Dear ladies and gentlemen, welcome to the Merck investor and analyst conference call on second quarter 2025. (Operator Instructions) I now hand it over to Florian Schraeder, Head of Investor Relations, who will lead you through this conference. Please go ahead, sir.
Thank you very much, Heidi, and heartfelt welcome to the Merck Q2 '25 results call. I am Florian Schraeder, the Head of Investor Relations at Merck. It is my pleasure to be joined today by Belen Garijo, our Group CEO; and Helene von Roeder, our Group CFO.
For the Q&A segment of this call, we will also have Jean-Charles Wirth, CEO Life Science; Danny Bar-Zohar, CEO of Healthcare; and Kai Beckmann, CEO Electronics, with us. In the initial minutes of this call, we will guide you through the key slides of the presentation. Following that, we will be glad to address your questions.
With that, I would like to hand it over to Belen to begin.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
